Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice
10 Feb, 2022
Authors: F Malik, V Chulanov, N Pimenov, A Fomicheva, R Lundin, N Levina, C Thorne, A Turkova, G Indofi Published in: The Journal of viral elimination
Read More
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
30 Dec, 2021
Authors: A Turkova, E White, HA. Mujuru, AR. Kekitiinwa, CM. Kityo, A Violari, A Lugemwa, TR. Cressey, P Musoke, E Variava, MF. Cotton, M Archary, et al for the ODYSSEY Trial…
Read More
Size of HIV-1 reservoir is associated with telomere shortening and immunosenescence in early-treated European children with perinatally acquired HIV-1
17 Dec, 2021
Authors: A Dalzini, G Ballin, S Dominguez-Rodriguez, P Rojo , M.R Petrara, C Foster, N Cotugno, A Ruggiero, E Nastouli, N Klein, S Rinaldi, S Pahwa, P Rossi, C Giaquinto,…
Read More
Dolutegravir-based ART is superior to standard of care ART in young children <14kg living with HIV
11 Dec, 2021
Authors: Kaudha E on behalf of the ODYSSEY trial Presented at: PEPFAR Uganda Science Summit
Read More
Diaskin and tuberculin skin test as tuberculosis diagnostics in Russian children: comparative observational study
09 Dec, 2021
Authors: Fritschi N, Gureva T, Eliseev P, Crichton S ,Intira Jeannie Collins IJ, Turkova T, Mariandyshev A, Ritz N Presented at: The 52nd Union World Conference On Lung Health 2021
Read More
Characterisation of the HIV proviral and inducible reservoir in well- suppressed children on long-term ART
06 Dec, 2021
Authors: Gärtner K, Byott M, Heaney J, Pagliuzza A, Spyer M.J Frampton D, Rossi A.D, Palmas P, Giaquinto C, Conejo P.R, Foster C, Rossi P, Klein N, Chomont N, Nastouli…
Read More
Dolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV (combined results of the main trial and the ‘under 14kg’ cohort)
28 Sep, 2021
Authors: Anna Turkova on behalf of the ODYSSEY trial team Presented at: CHIVA 2021
Read More
Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the main ODYSSEY trial (≥14kg)
03 Sep, 2021
Authors: White E and Kityo C on behalf of the ODYSSEY trial team Presented at: CHIVA 2021
Read More
No age-related difference in dolutegravir metabolic glucuronidation ratio in children between 3 months and 18 years old in the ODYSSEY trial
29 Jul, 2021
Authors: T.G Jacobs, A. Colbers, H. Waalewijn, P. Amuge, D. Bbuye, E. Kaudha, A. Nanduudu, S. Makumbi, L. Atwine, S. Mudzingwa, K. Nathoo, J. Hakim, A. Liberty, A.J. Van Rensburg,…
Read More
Effect of dolutegravir on folate and vitamin B12 status among HIV- infected children and adolescents in the ODYSSEY trial
29 Jul, 2021
Authors: L. Barlow-Mosha, G. Ahimbisibwe, E. Chappell, P.M. Amuge, A. Nanduudu, E. Kaudha, T. Amukele, D. Balamusani, B. Kafufu, A. Nimwesiga, C. Kityo, A.R Kekitiinwa, R. Namwanje, G. Kasangaki, A.…
Read More
Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial
29 Jul, 2021
Authors: E White, A Turkova, HA Mujuru, I Nankya, B Wynne, S Ali, A Kekitiinwa, A Lugemwa, E Kaudha, A Liberty, H Cassim, M Archary, M Cotton, L Barlow-Mosha, TR…
Read More
Dolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV (combined results of the main trial and the ‘under 14kg’ cohort)
29 Jul, 2021
Authors: Turkova A on behalf of the ODYSSEY trial team Presented at: CHIVA 2021
Read More
Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial
29 Jul, 2021
Authors: A Turkova, A Kekitiinwa, E White, V Mumbiro, E Khauda, A Liberty, E Dobbels, GM Ahimbisibwe, T Moloantoa, L Atwine, S Kanjanavanit, NR Mosia, T Puthanakit, T Smit, R…
Read More
Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial
29 Jul, 2021
Authors: Violari A, Kekitiinwa A, White E, Mumbiro V, Rutebarika D, Dobbels E, Kataike H, Moloantoa T, Atwine L, Nazzinda R, Mbabazi R, Kanjanavanit S, Mosia N, Na-Rajsimax S, Techakunakorn…
Read More
Effect of dolutegravir on folate and vitamin B12 status among HIV- infected children and adolescents in the ODYSSEY trial
29 Jul, 2021
Authors: L. Barlow-Mosha, G. Ahimbisibwe, E. Chappell, P.M. Amuge, A. Nanduudu, E. Kaudha, T. Amukele, D. Balamusani, B. Kafufu, A. Nimwesiga, C. Kityo, A.R Kekitiinwa, R. Namwanje, G. Kasangaki, A.…
Read More
Dolutegravir-Based ART is Superior to Standard of Care in Young Children Living With HIV
29 Jul, 2021
Authors: P Amuge on behalf of the ODYSSEY trial team Published in: International workshop on HIV pediatrics 2021 Abstract Background: ODYSSEY, a multi-country randomised trial, demonstrated superior treatment efficacy…
Read More
Weight Gain in Children and Adolescents on Dolutegravir vs Standard-of-Care in the ODYSSEY Trial
29 Jul, 2021
Authors: Mujuru H , Lugemwa A, Puthanakit T, Amuge P, Kityo C, Compagnucci A, Variava E, Kekitiinwa A, Musiime V, BarlowMosha L, Ngampiyaskul C, Zuidewind P, Tumusiime J, Mngqbisa R,…
Read More
A randomised comparison of DTG-based ART vs Standard of Care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial
29 Jul, 2021
Authors: A Lugemwa, H Mujuru, B Wynne, A Violari, AR Kekitiinwa, CM Kity, M Archary, E Variava, T Sarfati, C Shakeshaft, R Turner, K Nathoo, E Chidziva, L Atwine, N…
Read More